Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis

Jelena Vojinović,Ivan Foeldvari,Joke Dehoorne,Violeta Panaviene,Gordana Susic,Gerd Horneff,Valda Stanevica,Katarzyna Kobusinska,Zbigniew Zuber,Bogna Dobrzyniecka,Tadej Avcin,Cecilia Borlenghi,Edmund Arthur,Chuanbo Zang,Vassilis Tsekouras,Bonnie Vlahos,Alberto Martini,Nicolino Ruperto,Paediatric Rheumatology International Trials Organisation (PRINTO)

DOI: https://doi.org/10.1007/s40744-024-00703-z

Abstract:This is a summary of the original article 'Ten-year safety and clinical benefit from open label etanercept treatment in children and young adults with juvenile idiopathic arthritis'. Juvenile idiopathic arthritis (JIA) usually appears before the age of 16. JIA causes pain, swelling, and stiffness in the joints. People with JIA receive treatment for several years until the disease goes into prolonged remission. Therefore, the long-term safety of these treatments is an important topic. Etanercept is a treatment for JIA, which acts on the body's immune system to reduce arthritis. This summary of research article describes safety and how well etanercept works in children with JIA taking it for up to 10 years.